ADA and COVID-19: Thus, we assume that ADA1 can be recognized as a natural antagonist that blocks viral attack and ameliorates a severe course of SARS-CoV-2 infection, but at the same time, it may be a cause of long-term vascular complications after mild/moderate COVID-19 due to adenosine signaling modulation and its role as an adhesion molecule.